Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo’s chemical conjugation method, which uses high drug-to-antibody ratio (DAR) technology, was approved by the U.S. Food and Drug Administration as the first site-specific ADC (fam-trastuzumab-deruxtecan-nxki; Enhertu® | Daiichi Sankyo and AstraZeneca).

However, owing to limitations in high-DAR technology and the potential need for DAR=2 production, the Ajinomoto group has been developing a chemical site-specific conjugation technology using Fc-affinity peptide reagents since 2019 [2]. This approach modifies a specific lysine in the Fc region of various antibodies such as IgG1, IgG2, and IgG4 to create homogeneous DAR=2 ADCs, as demonstrated in a proof-of-concept study.

Read Full Article

Authors: Tomohiro Fujii, Ph.D.1, and Yutaka Matsuda, Ph.D, Ph.D, MBA,2

Advertisement #3 

Corresponding Author: Tomohiro Fujii, Ph.D

Key terms: ADC, antibody-drug conjugate, drug-to-antibody ratio, DAR, chemical conjugation, site-specific conjugation, Fc affinity peptide conjugation, AJICAP
Published In: ADC Review| Journal of Antibody-drug Conjugates

DOI: https://doi.org/10.14229/jadc.2023.07.28.003.

How to cite:

Tomohiro Fujii1, Yutaka Matsuda2
AJICAP Second-generation: Realizing Versatility and Robustness through Fc-Affinity Guided Chemical Conjugation Technology – J. ADC. July 28, 2023. DOI: 10.14229/jadc.2023.07.28.003.

1 Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
2 Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, CA 92121, United States

Last Editorial Review: July 12, 2023

Creative Commons License

Article History:

  • Original Manuscript Received May 23, 2023
  • Review results received July 17, 2022
  • Manuscript accepted for publication  July 28, 2023

Featured Image: Manufacturing at Aji Bio-Pharma. Courtesy: © 2010 – 2018 Aji Bio-Pharma. Used with permission.


Advertisement #4